Overview

Location [1]
7p22.3
Protein [2]
Mitotic spindle assembly checkpoint protein MAD1
Synonyms [1]
TXBP181, PIG9, MAD1, TP53I9

MAD1L1 is altered in 0.07% of all cancers with low-grade glioma, NOS, pancreatic adenocarcinoma, pilocytic astrocytoma, thyroid gland papillary carcinoma, and astrocytoma having the greatest prevalence of alterations [3].

MAD1L1 GENIE Cases - Top Diseases

The most common alterations in MAD1L1 are MAD1L1-BRAF Fusion (0.06%), MAD1L1-ALK Fusion (0.09%), MAD1L1-CDKN1B Fusion (0.02%), and MAD1L1-RAF1 Fusion (0.02%) [3].

MAD1L1 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.